JKJeremy J. Kodanko

Jeremy J. Kodanko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeremy J. Kodanko has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond IC 50 : Reframing Microcystin Potency against Protein Phosphatase 2A by Defining Two-Step Irreversible Inhibition Kinetics

    by Kelli N. Hummel, Blake B. Stringer, Sharmila I. Thenuwara, Judy A. Westrick, Jeremy J. Kodanko

    Microcystins (MCs) are among the most potent natural inhibitors of serine/threonine protein phosphatases, yet their toxicity is typically assessed using IC50 values that obscure the underlying kinetics and mechanism of enzyme inactivation. Here, we present a comprehensive kinetic analysis of protein phosphatase 2A (PP2A) inhibition by a panel of structurally diverse MC congeners, including MC-LR, MC-LA, MC-LW, MC-RR, [d-Asp3] MC-LR, and the noncovalent control [d-Asp3][Dhb7] MC-RR. Using an established PP2A inhibition assay method and modeling software to determine Ki, kinact, and kinact/Ki, we resolved reversible binding from covalent inactivation to characterize the two-step inhibition mechanism. All covalently competent MCs bind PP2A with picomolar affinity (Ki ≈ 3–11 pM) and undergo slow but tightly constrained covalent modification of Cys269 (kinact ≈ 3–5 × 10–4 s–1), yielding near–diffusion-limited inactivation efficiencies (kinact/Ki ≈ 107–108 M–1 s–1). Structural variation among congeners primarily modulates binding equilibrium and the fraction of complexes that achieve a productive geometry for covalent bond formation, while the irreversible inactivation step remains relatively similar. Notably, [d-Asp3][Dhb7] MC-RR binds PP2A with picomolar affinity despite lacking a highly reactive electrophile, demonstrating that high-affinity engagement is mechanistically separable from covalent inactivation. These results reveal that MC potency is driven by exceptionally tight and persistent PP2A binding rather than fast reactivity, providing a kinetic framework that links molecular structure to sustained phosphatase inactivation and real-world toxicity during harmful algal bloom exposure.


  • Open Access

    Structure–Activity Relationships of Anabaenopeptins as Carboxypeptidase and Phosphatase Inhibitors

    by Megan L. Quandt, Judy Westrick, Jeremy J. Kodanko

    Anabaenopeptins are a family of cyanobacterial cyclic peptides that display potent enzyme inhibition, particularly against carboxypeptidases A and B, as well as the serine/threonine phosphatases PP1 and PP2A. Defined by a 19-membered macrocyclic ring and a ureido-linked exocyclic amino acid, these compounds vary considerably in their amino acid composition, influencing both potency and selectivity. This review compiles published IC50 values for natural and synthetic anabaenopeptins, organizing them by enzyme target, and highlighting recurring structural motifs that drive inhibitory activity. Through this comparative analysis, we identify emerging trends in structure-activity relationships and underscore gaps in assay standardization and structural validation. These insights provide a critical foundation for advancing the biological evaluation of anabaenopeptins as environmental contaminants, mechanistic probes, and candidate scaffolds for therapeutic development.


  • Leveraging Intramolecular π-Stacking in Ru(II)-Pyridine Complexes to Induce Photoinduced Ligand Dissociation

    by Alexia Marques Silva, Austin P. Lanquist, Curtis E. Moore, Randolph P. Thummel, Jeremy J. Kodanko, Claudia Turro

    [Ru(tpy)(L)(py)]2+ (tpy = 2,2;6'2″-terpyridine; py = pyridine), where L represents 1,10-phenanthroline (1; phen), 2-phenyl-1,10-phenanthroline (2; phenyl-phen), and 2-(1'-pyrenyl)-1,10-phenanthroline (3; pyrenyl-phen), were synthesized and characterized by 1D and 2D 1H NMR and through X-ray crystallography. These methods show that 2 and 3 exhibit intramolecular, interligand π-stacking between the phenyl and pyrenyl groups of the substituted phen ligands in 2 and 3, respectively, and the tpy ligand in each complex. DFT calculations show that the deviation from octahedral geometry around the metal in 2 and 3 leads to a lower energy eg-type orbital set with Ru-py(σ*) character, making the dissociative metal-centered (MC) excited state(s) more accessible from the metal-to-ligand charge transfer (MLCT) states in these complexes relative to 1. The lifetimes of the lowest energy Ru→tpy 3MLCT excited states in 2 and 3 are shorter than that of 1, consistent with the more facile 3MLCT deactivation through the 3MC state(s) in 2 and 3 as compared to 1. Complexes 2 and 3 undergo pyridine ligand exchange with a Cl- ion in CH2Cl2 with quantum yields, Φ450, of 0.024(2) and Φ450 = 0.019(3), respectively (λirr = 450 nm), representing a > 100-fold increase as compared to that of 1, Φ450 < 10-4. The increase in photoinduced ligand exchange in 2 and 3 is attributed to the greater population of the dissociative 3MC state(s) in these complexes. This represents the first demonstration that intramolecular π-stacking in Ru(II) complexes can be used to enhance ligand release upon irradiation, highlighting a new method to achieve more efficient delivery of pyridine-containing drugs for photochemotherapy.


  • Cytochrome P450 Induction through the Efficient Photoinduced Release of a Pyridine-Substituted Agent from Ru(II)

    by Kelli Hummel, Sayak Gupta, Alexia Marques Silva, Santana P. Garcia, Donna H. Odhiambo, Dylan Sygit, Juan Cai, Cassandra Ward, Thomas Kocarek, Alexander Yu. Sokolov, et al.

    We report the first example of using photoinduced ligand release from a Ru(II) complex for light-triggered cytochrome P450 (CYP) induction. CYPs are pivotal enzymes in biosynthesis and drug metabolism, and their induction can be leveraged for therapeutics and biochemical research. We show the activation of a CYP1A1 with visible light through the efficient photorelease of an aryl hydrocarbon receptor (AHR; 1) agonist with a quantum yield, Φ500, of 0.16(1) with λirr = 500 nm in [Ru(tpy)(Me2bpy)(1)]2+ (tpy = 2,2':6',2″-terpyridine, Me2bpy = 6,6'-dimethyl-2,2'-bipyridine). This value is consistent with that previously reported for pyridine (py) exchange in the analogous [Ru(tpy)(Me2bpy)(py)]2+ complex, Φ500 = 0.16(1), which is driven by steric effects. In contrast to [Ru(tpy)(bpy)(py)]2+ (bpy = 2,2'-bipyridine), with Φ500 < 10-4, the ligand photodissociation in [Ru(tpy)(bpy)(1)]2+ proceeds with Φ500 = 0.015(1), at least 2 orders of magnitude more efficiently. Similarly, [Ru(tpy)(biq)(1)]2+ (4; biq = 2,2'-biquinoline) undergoes photoinduced exchange of 1 with CH3CN solvent with Φ500 = 0.064(3), more efficiently than [Ru(tpy)(biq)(py)]2+ with Φ500 = 0.03. Through experiments and calculations, we show the involvement of intraligand charge transfer (ILCT) within the leaving ligand in an unprecedented mechanism for ligand photodissociation from Ru(II). Chemical tools based on these findings hold the promise of advancing research on tissue-specific CYP activity by enabling precise spatiotemporal control. Moreover, these compounds may pave the way for the development of highly specific and light-activated pharmaceuticals that enhance the synergy with existing drugs.


  • A Highly Convergent Synthesis Route for Adda: A Non-Proteinogenic Amino Acid Unit in Cyanobacteria

    by Meher Prakash, Naresh M. Venneti, Judy Westrick, Jeremy J. Kodanko

    We report a concise nine-step synthesis of Boc-Adda-OH, a key residue in bioactive cyanobacterial peptides. The route features a regio- and stereoselective intermolecular Heck reaction to form a stable isoxazolidin-5-one, followed by N-O bond cleavage. This efficient, convergent approach offers excellent stereocontrol and functional group tolerance, facilitating access to Adda for natural product synthesis, environmental monitoring, and toxicological studies.


  • Open Access

    Structure, Toxicity, Prevalence, and Degradation of Six Understudied Freshwater Cyanopeptides

    by Blake B. Stringer, Regina G. Szlag Silva, Jeremy J. Kodanko, Judy A. Westrick

    Anthropogenic influences have increased global warming and eutrophication, escalating the frequency and severity of harmful cyanobacterial blooms (cHABs) in freshwater ecosystems. These blooms release cyanopeptides, a diverse class of bioactive compounds with varying acute and chronic toxicities upon ingestion. To date, research has prioritized acutely toxic cyanopeptides like microcystins. As a result, significantly less is known about other freshwater cyanopeptides. This review highlights six understudied cyanopeptide classes, anabaenopeptins, cyanopeptolins, aeruginosamides, aeruginosins, microginins, and cyclamides, and provides a comprehensive overview of their molecular structures, toxicological profiles, environmental concentrations, and known degradation pathways. Given the potential toxicity, increased environmental abundance, and environmental stability of many cyanopeptides in freshwater sources, further research is needed to understand if degraded cyanopeptides are still biologically active prior to entering drinking water to ensure public health.


  • Sustainable Protein Conjugates as a Soluble Capture and Release System for Lanthanides

    by Elliot Furr, Sayak Gupta, Sai Praneeth, Matthew J. Allen, Timothy M. Dittrich, Jeremy J. Kodanko


  • Mixed Ru(II)–Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4

    by Justin J. Ahrens, Madeline Denison, Santana Garcia, Sayak Gupta, Thomas A. Kocarek, Irina F. Sevrioukova, Claudia Turro, Jeremy J. Kodanko

    Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme in human drug metabolism. To garner photochemical control over the inhibition of CYP3A4, a potent Ir(III)-based inhibitor of CYP3A4 was complexed with two Ru(II)-based photocaging groups. Chemical, photochemical, and biological properties of the photocaged inhibitors were characterized. Importantly, mixed Ru(II)-Ir(III) complexes strongly absorb green light, which facilitates the photochemical release of the Ir(III) inhibitor from the Ru(II) caging fragment [Ru(tpy)(Me2bpy)]2+, where tpy = 2,2':6',2″-terpyridine and Me2bpy = 6,6'-dimethyl-2,2'-bipyridine. Emission turn on, type II heme binding, and more potent inhibition under light vs dark conditions were observed. The study also demonstrated that a Ru(II)-Ir(III) conjugate can be photoactivated to exert cytotoxic effects on MCF-7 breast cancer cells upon green light exposure. Additionally, a synthesized analogue with one [Ru(TPA)]2+ fragment (TPA = tris(pyridin-2-ylmethyl)amine) and two Ir(III) centers, although resistant to photochemical release, showed strong inhibition of CYP3A4 both in purified form and in CYP3A4-overexpressing HepG2 cells, with nanomolar potency. These mixed Ru(II)-Ir(III) compounds can permeate cell membranes and inhibit CYP3A4, presenting a new class of bioactive compounds.


  • Open Access

    Ru(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death

    by Madeline Denison, Alexander Ullrich, Mackenzie K. Herroon, Shane Mecca, Claudia Turro, Izabela Podgorski, Heather Gibson, Jeremy J. Kodanko

    Immunotherapy has emerged as a promising avenue for cancer treatment by bolstering the immune system’s ability to recognize and attack cancer cells. Photodynamic therapy shows potential in enhancing antitumor immunity, though the mechanisms behind its success are not fully understood. In this manuscript, we investigate two previously reported green light activated PCT/PDT agents where compound 2 - [Ru(tpy)(Me2bpy)( 3 )] 2+ , (tpy = 2,2’:6’,2’’- terpyridine, Me2bpy = 6,6’-dimethyl-2,2’-bipyridine, 3 = pyridyl-BODIPY-I2,) - shows remarkable photoselectivity in assays containing both 2D cancer cells and 3D cocultures containing BALB/c macrophages and 4T1 murine breast cancer cells. Through flow cytometry and protein analysis, we found complex 2 displays superior evidence of induced endoplasmic reticulum (ER) stress markers and indicators of immunogenic cell death (ICD) compared to its ligand 3 , despite its weaker photoselectivity. Most importantly, these results were supported by in vivo studies where 2 produced anti-tumor immunity against the 4T1 tumor model in BALB/c mice. Complete tumor elimination was achieved in 2/8 mice, and these mice were both protected against a subsequent contralateral rechallenge and showed increased ex vivo peripheral tumor antigen-specific recall, suggesting memory T cells are induced by 2 . Signatures of M1 macrophage polarization were also evident in tumor tissue from the remaining 6/8 mice treated with 2 compared to untreated tumors. These findings demonstrate Ru(II) complexation plays a critical role in ER targeting which triggers ICD, highlighting the potential of Ru(II) agents as future in situ tumor vaccines.